Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, has launched its Center of Excellence for Biologics and Cell and Gene Therapy in Research Triangle Park (RTP), North Carolina. The new facility expands the company’s global footprint and
Lantheus Holdings, Inc., a radiopharmaceutical company, has announced an agreement to acquire Evergreen Theragnostics, Inc., this includes a $250 million upfront payment and milestone-based payouts of $752.5 million. The transaction is expected to close in the second half of 2025,
Amgen celebrated the official opening of its state-of-the-art drug substance manufacturing facility in Holly Springs, North Carolina, on January 24. The event, which featured a ribbon-cutting ceremony, marked the first phase of the company’s $1.5 billion investment in the region.
Alvotech, a global biotech company focused on biosimilars, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration (FDA) has accepted their Biologics License Applications (BLAs) for AVT05. The proposed biosimilar
“The Americans put a man on the moon in less time than it takes us to transfer a product between countries – this has to change,” says Luiz Barberini, who leads External Manufacturing for Bayer Consumer Health across Latin America.
Ascentage Pharma, a China-based biotechnology firm, raised $126 million in its US initial public offering (IPO), marking the first biotech IPO of 2025. The company sold 7,325,000 American Depositary Shares (ADS) at $17.25 each. Trading began on 24 January on
AbbVie has entered into a collaboration and option-to-license agreement with Neomorph, Inc. to advance the development of molecular glue degraders for oncology and immunology. The partnership aims to tackle challenging and historically “undruggable” protein targets by leveraging molecular glue degraders—a
Disc Medicine, Inc., a clinical-stage biopharmaceutical company, has announced the pricing of its upsized underwritten public offering. The offering includes 3,918,182 shares of common stock priced at $55.00 per share and pre-funded warrants for 181,818 shares priced at $54.9999 per
ReiThera has entered into a Master Service Agreement (MSA) with SillaJen to support the manufacturing of the SJ-600 series, an innovative anticancer virus platform. The agreement appoints ReiThera as the Contract Development and Manufacturing Organization (CDMO) for the platform, enabling
The Netherlands has emerged as one of Europe’s most vibrant and interconnected biotech ecosystems, home to over 1,797 life science companies, world-class pharmaceutical manufacturers, and the European Medicines Agency. With its strategic location, exceptional infrastructure, and collaborative spirit, the country
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
